



GenomeCanada

2012 Large-Scale Applied Research Project Competition

Genomics and Personalized Health

Criteria for Evaluating Pre-Applications

Eligibility Criteria

Each pre-application will be reviewed for eligibility. The following criteria will be used.

Does the proposal:

- respond to the objectives of the Genome Canada competition as described in the RFA;
- include genomics approaches as essential components in terms of importance to the overall outcomes of the project;
- address personalized health in humans; and,
- possess a scale and scope such that it is able to address challenges requiring a genomics approach, be internationally competitive and have potential to have a major impact?

If considered eligible, the pre-application will be reviewed using the criteria described below.

Review Criteria

There are two main areas of evaluation that will be scored:

- Research Proposal
- Socio-Economic Benefits for Canada

In addition, reviewers will be asked to comment on the Management and Financial aspects of the pre-application.

1. Research Proposal

Including Research on Ethical, Environmental, Economic, Legal and Social Aspects of Genomics (GE³LS)

- Research Context and Originality
 - To what extent does the proposed research lead, extend and/or complement national and international work in the area?
 - To what extent does the proposed research reflect creative, original thinking?

- Research Plans
 - How appropriate is the proposed approach given the objectives of the outlined research?
 - How feasible is the research given the projected resources and time-lines?
 - If the main focus of the research project is genomics, does the integrated GE³LS investigation address salient aspects of the genomics project and are the research questions directly related to the objectives and expected outcomes?
- Research Expertise
 - How appropriate is the expertise of the research team in terms of realizing the research goals?

2. Socio-Economic Benefits for Canada

- Deliverables
 - To what extent have the applicants identified appropriate deliverables in terms of their potential to have clinical utility and/or practical applicability?
 - What is the probability that the deliverables will be achieved by the end of the funding period?
- Expected Benefits
 - How significant are the anticipated benefits described in the proposal in terms of their potential of contributing to a more evidence-based approach to health and improved cost-effectiveness of the health-care system?
- Strategy for Realizing Benefits
 - How persuasive is the strategy set out by the applicants for realizing benefits from their research?
 - How appropriate is the expertise for implementing a strategy to realize benefits?
 - To what extent are likely end-users involved in the project and the strategy to realize benefits?
 - Will the benefits be realized within a short time-frame after the end of the project?

Note: All else being equal between two proposals, the one which makes a stronger case for benefits to be achieved sooner will be assessed more favourably.

3. Management and Financial Criteria

- Management
 - How appropriate is the proposed management plan?
 - What is the potential for the team to be able to make critical decisions regarding the overall research direction?
 - To what extent does the team have the expertise for managing large-scale projects that involve research and the application of results?
- Financial
 - Do the budgeted costs meet the definition of Eligible Costs (see Section 7.1, Guidelines for Funding Large-Scale Genomics Research Projects, December 2011)?
 - Are the budgeted costs aligned with the proposed research plan?
 - Are the budgeted costs reasonable relative to the research to be conducted, the methodologies used, and the deliverables expected ?
 - Does the proposed co-funding comply with the guidelines for Eligible Co-funding (see Section 7.2, Guidelines for Funding Large-Scale Genomics Research Projects)?
 - Is the proposed co-funding plan feasible, that is, what is the likelihood of the project being able to secure at least 75% of the co-funding for eligible costs at the time of the release of funds?